购物车
- 全部删除
- 您的购物车当前为空
AM-2394 是新型的 glucokinase 激活剂 (GKA)。它能够激活葡萄糖激酶 (GK),EC50=60 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
AM-2394 是新型的 glucokinase 激活剂 (GKA)。它能够激活葡萄糖激酶 (GK),EC50=60 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 266 | 现货 | |
5 mg | ¥ 619 | 现货 | |
10 mg | ¥ 993 | 现货 | |
25 mg | ¥ 1,880 | 现货 | |
50 mg | ¥ 2,980 | 现货 | |
100 mg | ¥ 4,560 | 现货 | |
200 mg | ¥ 6,390 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 683 | 现货 |
产品描述 | AM-2394 is an effective and specific Glucokinase agonist (GKA, EC50: 60 nM), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. AM-2394(AM2394) increases the affinity of GK for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models, and lowers glucose excursion following an oral glucose tolerance test in an ob/ob mouse model of diabetes. |
靶点活性 | GKA:60 nM(EC50) |
体内活性 | AM-2394是一种结构独特的葡萄糖激酶激活剂,在ob/ob小鼠进行口服葡萄糖耐量测试(OGTT)时,以3 mg/kg的剂量显著降低血浆葡萄糖水平。AM-2394使葡萄糖激酶(GK)对葡萄糖的亲和力提高了大约10倍,并在多种动物模型中表现出适中的清除率和良好的口服生物利用度,降低了ob/ob小鼠糖尿病模型在口服葡萄糖耐量测试后的葡萄糖波动。AM-2394在跨物种血浆清除率、分布体积和口服生物利用度方面展现出良好到适中的效果,允许在动物模型中进一步评估[1]。 |
激酶实验 | Kinase screen: Briefly, all assays (25.5 μl at 21°C for 30 min) are performed using a Biomek 2000 Laboratory Automation Workstation in a 96-well format. Reactions contains 5–20 mU purified kinase along with substrate peptide or protein and are initiated by the addition of 10 mM MgAcetate and 5, 20, or 50 μM ATP ([γ-33P]-ATP, 800 cpm/pmol). |
别名 | AM2394 |
分子量 | 423.46 |
分子式 | C22H25N5O4 |
CAS No. | 1442684-77-6 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (118.15 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.